Sign in

Gleevec

2001Big moment

Imatinib, designed to block the protein made by the Philadelphia chromosome, turns chronic myeloid leukemia into a manageable disease and proves targeted cancer drugs work.

The story

On May 10, 2001, the U.S. Food and Drug Administration approved imatinib, sold as Gleevec, for chronic myeloid leukemia (CML), a blood cancer. The agency took only about two and a half months, one of its fastest approvals. In early trials, 53 of 54 patients given adequate doses saw their blood counts return to normal. Before the drug, CML typically killed within three to six years of diagnosis, and the only cure was a risky bone marrow transplant. Today patients who respond to imatinib have near-normal life expectancy, and about 89 percent were alive after five years in a large trial.

The drug was designed using a discovery stretching back four decades. In 1960 Peter Nowell and David Hungerford noticed that CML cells share an abnormally short chromosome, named the Philadelphia chromosome for the city where they worked. In 1973 Janet Rowley showed that it is formed when pieces of chromosomes 9 and 22 swap places, and in the 1980s scientists found that the swap fuses two genes, BCR and ABL, creating a protein that acts as an enzyme stuck in the on position, called a tyrosine kinase, which drives the cells to multiply. Chemotherapy had given only brief remissions and hit healthy cells as well.

Nicholas Lydon and colleagues at the Swiss company Ciba-Geigy (later Novartis) searched for a molecule that would fit into the enzyme's active site and block it. Brian Druker, then at Oregon Health and Science University, showed that the compound killed CML cells and pushed a hesitant company to test it in patients, since CML was a rare disease with a small market. Charles Sawyers helped extend the work to patients whose disease relapsed. Resistance can develop, which led to later drugs such as dasatinib and nilotinib. Gleevec proved that a drug aimed at the exact molecular cause of a cancer can work, opening the era of targeted therapy.

Why it mattered

  • Targeted cancer drugs became a major class of treatment, with many kinase inhibitors following for lung, breast, kidney and other cancers.
  • Sequencing tumors to find their driver mutations became routine, supporting what is called precision medicine.
  • Second-generation drugs for resistant CML were developed, showing how to answer resistance with new molecules.
  • The high price of cancer drugs became a public debate, as annual costs rose from about 30,000 dollars until generics appeared.

Drafted by AI (Claude) from the sources above and checked against them by AI; no historian has reviewed this page. Spot a mistake? Suggest a correction. How pages are made

Community notes

Loading notes…

Learn more ranked by votes

BookJessica Wapner
The Philadelphia Chromosome
Search Open Library
VideoSearch YouTube
Gleevec imatinib story
Search YouTube